But it seems clear to me that Glaxo have secured Relenza sales as part of the deal to allow the four UK govts to cut back on original swine flu vaccines ordered and therefore Glaxo is indeed in a very good and unique position to do this with other governments.
"The H5NI vaccine and Relenza will be purchased as part of the agreement and are both licensed for use in the UK".
You've been on the sidelines lately. You called in comments from a usual suspect who is also a non-holder. Out came the same old chart and call that the stock is heading down to around $2.00 and possibly lower, plus the usual baiting to boot. Your comment was respect.
How about a call on where you think this is headed? Everyone else is making a call, even the little shy1.
BTA Price at posting:
$2.33 Sentiment: LT Buy Disclosure: Held
